The record
| Class | anti inflammatory |
|---|---|
| Also known as | α-MSH(11-13), Alpha-MSH fragment 11-13, KPV tripeptide |
| Chain length | - |
| Molecular weight | 342.4 Da |
| Half-life | <30 minutes (but intracellular effects persist) |
| Route | Oral, topical, or SC |
| Studied for | - |
| Research use | IBD models (oral delivery); Wound healing (topical); Anti-inflammatory research |
| What has been shown | Reduces intestinal inflammation (DSS/TNBS colitis models); Accelerates wound healing; No pigmentary effects (unlike α-MSH); Orally active (GI stable) |
| How it works | C-terminal tripeptide of α-MSH with potent anti-inflammatory activity but no melanogenic effects. Acts via: (1) Direct cellular uptake (PepT1/2 transporters), (2) Intracellular targets (not MC1R), (3) NF-κB pathway inhibition, (4) Reduced inflammatory cytokines (TNF-α, IL-1β, IL-6), (5) Increased anti-inflammatory IL-10. Penetrates cells directly, making it effective topically and orally. |
| Patent status | Various formulation patents |
| Regulatory status | Research/cosmetic use |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- GI Barrier / Gut Integrity (affection, 52%)
- GI Inflammation Modulation (affection, 85%)
- Inflammation Modulation (affection, 67%)
- Anti-biofilm treatment (illness, 30%)
- Antimicrobial applications (illness, 30%)
- Cancer immunotherapy adjuvant (illness, 60%)
- COVID-19 (illness, 60%)
- Hepatitis B/C treatment (illness, 60%)
- Immunomodulation (illness, 30%)
- Sepsis treatment (illness, 60%)
- Sepsis/endotoxemia protection (illness, 30%)
- Vaccine adjuvant (illness, 60%)
- Pain (symptom, 50%)
- Frequent infections (symptom, 100%)
- Swelling or inflammation (symptom, 50%)